Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews

Tafelski, Sascha; Haüser, Winfried; Schäfer, Michael

doi:10.1007/s00482-015-0092-3

Cited by 57 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a case–control study conducted on 163 young men with testicular cancer and 292 control men, the men who had smoked cannabis presented twice as much risk of developing a form of testicular cancer with a poor prognosis compared to those who had not smoked any . Several studies reinforce this view . Nevertheless, in 2017, a Swedish epidemiologic study included near 50 000 men from 1970 to 2011 found no relationships between lifetime ‘ever’ cannabis use and the development of testicular cancer and only heavy cannabis users were associated with a higher incidence of testicular cancer .…”

Section: Social Usage Of Cannabis In Cancermentioning

confidence: 99%

Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review

Bouquié

Deslandes

Mazaré

et al. 2018

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Cannabis is a plant that has been used for centuries to relieve a wide range of symptoms. Since the 1960s, interest in medical research into this plant has grown steadily. Already very popular for recreational use, a growing number of consumers not accustomed to using cannabis for psychoactive purposes have begun to use it as an alternative or complement to mainstream pharmaceutical medicines. The principal unsubstantiated or 'social' uses of cannabis are based mainly on data that is at best controversial, but usually not scientifically proven. The aim of this review was to identify the scientific basis and reasons that lead patients with cancer to consume cannabis, and also to identify whether there is a risk of interaction between cannabis and anticancer medicines through drug transporters (P-glycoprotein and other ATP-binding cassette superfamily members) Cytochromes P450 (3A, 1A, 2B, 2C, 2D families…) and glucuronyl transferases.

show abstract

Section: Social Usage Of Cannabis In Cancermentioning

confidence: 99%

Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review

Bouquié

Deslandes

Mazaré

et al. 2018

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Only very few cannabis-based drugs, manufactured under stricter standards, are currently marketed under regulatory approval. [25][26][27][28][29] The oral administration of cannabinoids has several advantages: it is easier to consume, dose and composition are more tightly controlled, exposure time is longer, and side effects are considerably less intense. [17][18][19] The bioavailability of cannabinoids varies significantly by their mode of administration.…”

mentioning

confidence: 99%

Single‐Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology

Atsmon

Heffetz²,

Deutsch³

et al. 2017

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

Cannabidiol (CBD) is the main nonpsychoactive component of the cannabis plant. It has been associated with antiseizure, antioxidant, neuroprotective, anxiolytic, anti-inflammatory, antidepressant, and antipsychotic effects. PTL101 is an oral gelatin matrix pellets technology-based formulation containing highly purified CBD embedded in seamless gelatin matrix beadlets. Study objectives were to evaluate the safety and tolerability of PTL101 containing 10 and 100 mg CBD, following single administrations to healthy volunteers and to compare the pharmacokinetic profiles and relative bioavailability of CBD with Sativex oromucosal spray (the reference product) in a randomized, crossover study design. Administration of PTL101 containing 10 CBD, led to a 1.7-fold higher C and 1.3-fold higher AUC compared with the oromucosal spray. T following both modes of delivery was 3-3.5 hours postdosing. CBD exhibited about a 1-hour lag in absorption when delivered via PTL101. A 10-fold increase in the dose resulted in an ∼15-fold increase in C and AUC. Bioavailability of CBD in the 10-mg PTL101 dose was 134% relative to the reference spray. PTL101 is a pharmaceutical-grade, user-friendly oral formulation that demonstrated safe and efficient delivery of CBD and therefore could be an attractive candidate for therapeutic indications.

show abstract

“…The flowchart of the process of selection of the studies is presented in Figure 1. The list of excluded studies and the reasons for exclusions are stated in Table 2 (Barnes, 2002;Kinzbrunner, 2002;Tafelski, Häuser, & Schäfer, 2016;Verneda, 2002).…”

Section: Search Resultsmentioning

confidence: 99%

“…Nevertheless, other studies show some disparity. Smith et al (2015) concluded that prochlorperazine was similar to cannabinoids, as Machado Rocha concluded that prochlorperazine, alizapride, and Barnes (2002) Wrong study design Kinzbrunner (2002) Wrong study design Tafelski et al (2016) Wrong study design Verneda (2002) Wrong study design AMSTAR (a measurement tool to assess systematic reviews) items are as follows: 1 = a priori design; 2 = duplicate study selection and data extraction; 3 = comprehensive literature search; 4 = inclusive publication status; 5 = list of included/excluded studies provided; 6 = characteristics of included studies provided; 7 = quality assessment of studies; 8 = study quality used appropriately in formulating conclusions; 9 = appropriate methods used to combine studies; 10 = publication bias assessed; and 11 = conflict of interest stated. Scale for item score: 1 = Yes, 0 = No, Can't answer, or Not applicable.…”

Section: Cannabinoids Versus Other Antiemeticsmentioning

confidence: 99%

Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews

Schussel

Kenzo

Santos

et al. 2017

Phytotherapy Research

View full text Add to dashboard Cite

Nausea and vomiting are common and distressing adverse events of chemotherapy. This review focuses on the findings and quality of systematic reviews (SRs) of cannabinoids for chemotherapy-induced nausea and vomiting (CINV). Review of SRs, a systematic literature search, was conducted in several electronic databases and included SRs evaluating cannabinoids for CINV in cancer patients. Methodological quality and quality of reporting were evaluated by AMSTAR and PRISMA, respectively. Initial search retrieved 2,206 records, and 5 SRs were included. On the basis of findings of the sole SR judged as high methodological quality, cannabinoids seem to be more effective than placebo, equal to prochlorperazine for reducing CINV, and to be preferred by patients. The response to different combinations of antiemetic agents seems to be equal to 1 antiemetic alone. The average of AMSTAR score was 5, and the average of PRISMA score was 13.2. Cannabinoids represent a valuable option for treating CINV, despite the adverse events related to treatment, such as drowsiness and cognitive impairment. There is no good quality evidence to recommend or not the use of cannabinoids for CINV. More studies are still needed to evaluate the effectiveness of cannabinoids when compared with modern antiemetics.

show abstract

Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews

Cited by 57 publications

References 27 publications

Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review

Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review

Single‐Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology

Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews

Contact Info

Product

Resources

About